Abstract
METHODS:
A total of 104 patients with HCC were treated with HIFU and the efficacy was evaluated by the following indexes: tumor size, number, metastasis, alpha fetoprotein (AFP) levels before and after HIFU treatment, hepatic function before HIFU treatment, Child Pugh classifications, TNM stages and variations in color Doppler sonography.
RESULTS:
After HIFU treatment, the remission rates for clinical symptoms and liver function were 83.2% (80/104) and 82.7% (86/104), respectively, and the patients with AFP decreased by more than 50% covered a percentage of 62.5% (65/104). After HIFU, color Doppler sonography manifested coagulative necrosis and tumor blood supply reduction or disappearance in the target region. The survival rates of patients were 59.5% (3-6 mo), 38.7% (12 mo) and 25.6% (24 mo). The therapeutic effects of HIFU were correlated with AFP levels, TNM stages and treatment combined with transcatheter arterial chemoembolization and metastasis before treatment.
CONCLUSION:
HIFU is effective and feasible in the treatment of HCC, and its efficacy is associated with the pretherapeutic AFP levels, TNM stages and treatment combined with transcatheter arterial chemoembolization and metastasis. [8] , Ⅱb期8例、Ⅲ期49例、Ⅳ期47例.
对肝内残留复发肿瘤, 若患者病情许可, 1 mo后 进行再次行HIFU治疗.
1.2 方法 患者经临床体格检查及影像学检查确 定病灶位置、大小、形态和与邻近器官、血 管、胆管的关系. 根据上述资料确定治疗方案 [9] . 
